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Abstract 
The Sustainable Developmental Goals aim to se-
cure immediate human needs, such as adequate 
food supply and healthcare and provision of clean, 
affordable, and accessible energy. These achieve-
ments have to be imbedded in a sustainability 
concept. Bioeconomy is at the core of this con-
cept in which agricultural (plant) biotechnology 
plays a major role in delivering biomass for food, 
feed, and industry. Modern plant biotechnology 
comprises the genetic modification technology 
and various molecular biological tools which en-
hances the plant breeding potential. It results in 
increased food supplies, increased farm income 
worldwide, and reduced environmental damage. 
Here we review the innovations in plant biotech-
nology that are available on the market or at the 
late developmental stages and their application 
to agriculture, agroforestry, industrial processes, 
and pharmaceutical industry. Special emphasis is 
given to approaches adapted to meet heteroge-
neous local needs and help support more inclu-
sive growth in low and middle-income countries.
Introduction
In the 21st century, humanity is faced by a myr-
iad of socioeconomic and resource challenges 
to supply diverse emerging and recurrent global 
needs to feed, clothe, and fuel a population grow-
ing in size, age, and wealth. Pressure on resource 
competition and scarcity as well as the identifica-
tion, evaluation, and quantification of the impact 
of the human pressure on the planet have cata-
lysed a global concern on the sustainability of the 
continuous development of human societies. The 
Holocene – the warm period of the past 10-12 
millennia – is the only state of the planet that we 
know for sure to support contemporary human 
societies and is now being destabilized. Indeed, 
since the later part of the 18th century, the effects 
of humans on the global environment have grown 
so dramatically that a new geological era, the An-
thropocene, has been proposed (Crutzen, 2002). 
There is an urgent need of a paradigm shift to 
maintain the Earth System (ES) in a safely operat-
ing space for humanity. Sustainable developmen-
tal goals have to be implemented to guarantee 
immediate human needs, such as food supply, 
healthcare, and energy, alongside measures for 
a stable ES functioning. Nine critical processes/
features have been proposed to regulate the ES 
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functioning: climate change, biosphere integrity, 
land system change, freshwater use, biochemical 
flows, ocean acidification, atmospheric aerosol 
loading, stratospheric ozone depletion, and novel 
entities. Scientifically based planetary boundary 
levels of human perturbation have been estab-
lished for these ES processes/features, beyond 
which the ES functioning may be substantially al-
tered (Steffen et al., 2015).
 
Embedded in this emerging ES thinking, the new 
bioeconomy proposes a global transition toward 
sustainability through a bio-based industry that 
integrates the use of renewable aquatic, and 
terrestrial resources and biological processes to 
create energy, materials and products with an 
environmentally friendly footprint. Besides bioin-
dustry, bioeconomy also encompasses research, 
climate, environment, and development policies.
 
The deployment of bioeconomy relies on techno-
logical developments, among which biotechnology 
plays a key role. Biotechnology-based industry is 
an emerging reality that generates economic op-
portunities for agriculture, healthcare, chemical, 
and manufacturing sectors, with far-reaching po-
tential impacts on socio-economic developments 
and environment. According to the Biotechnology 
Global Industry Guide (www.researchandmarkets.
com/reports/41522/biotechnology_global_indus-
try_guide), the total revenues of the global biotech-
nology industry were US$ 323.1 billion in 2014, 
representing a compound annual growth rate of 
7.2% between 2010 and 2014. The biotech indus-
try is revolutionary beyond industrial growth be-
cause it offers opportunities for society to walk a 
different path toward multiple sustainable goals. In 
the energy and chemical sectors, biotech innova-
tion reduces dependence on petroleum and fossil 
fuels and, consequently, cleans the environment 
and fights global climate change. In the healthcare 
sector, the biotech industry has developed and 
commercialized drugs, vaccines, and diagnostics 
with significant impact on length and quality of 
life. In the agricultural field, biotech innovations 
simultaneously increase food supplies, reduce en-
vironmental damage, conserve natural resources 
of land, water, and nutrients, and increase farm 
income in economies worldwide.
 
The future of the biotech industry, more specifi-
cally, the industrial and agricultural sector, holds 
considerably in biomass production. Although 
biomass has since long been used as feedstock, 
e.g. wood-based materials, pulp and paper pro-
duction, biomass-derived fibers, the transition 
toward the modern bioeconomy requires the 
sustainable raw material production and efficient 
biomass use, implying a set of principles that 
should be strived for: (i) increased yields for food, 
feed, and industrial feedstock with as minimal as 
possible increases in land, water, fossil fuels, and 
minerals for fertilizer production; (ii) flowing use 
of biomass as food, feed, material, and, finally, 
energy; and (iii) cyclic reaction in which products 
should be designed for disassembly and reuse, 
consumables should be returned harmlessly to 
the biosphere, durables should maximise their re-
use or upgrade, and renewable energy should be 
used to energize the process (Mathijs et al., 2015).
 
Agriculture is central for global development pro-
motion within the biophysical limits of a stable 
ES. The conventional tools of intensive agricul-
tural growth, i.e., mechanization, plant breeding, 
agrochemicals, and irrigation, diminish returns 
and threaten the ES resilience. Four ES features 
transgress the proposed planetary boundary lev-
els: climate change, biosphere integrity, biogeo-
chemical flows, and land system changes (Steffen 
et al., 2015). As agriculture is the anthropogenic 
perturbation with the most prominent impact, it 
is challenged to produce sustainable yields. Of 
the novel technologies of several kinds needed 
to achieve sustainably high-yield agriculture, one 
of the most important implementation is modern 
plant biotechnology, i.e. genetically modified (GM) 
technology and various molecular biological tools, 
that enhances the plant breeding potential and 
reduces the negative impact both within fields 
and surrounding lands.
 
Plant GM technology originated back in the 
1980s, when the first GM plant, resistant to the 
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antibiotic kanamycin, had been developed (Van 
Montagu, 2011 and references therein; Angenon 
et al., 2013). In the 1970s, Jeff Schell, Marc Van 
Montagu, and colleagues at the Ghent University 
(Belgium), who studied the tumor-inducing princi-
ple of Agrobacterium tumefaciens, discovered that 
a large plasmid was responsible for the formation 
of crown galls on infected plants and that part of 
its DNA was transferred to plant cells (Zaenen et 
al., 1974; Van Larebeke et al., 1975; Depicker et 
al., 1978). After it had become clear that Agro-
bacterium could be used as a vector to transfer 
foreign DNA to plant cells, fertile transgenic to-
bacco (Nicotiana tabacum) plants were generat-
ed that expressed and transmitted the chimeric 
antibiotic resistance genes to their progeny. A 
first company on plant genetic engineering, Plant 
Genetic Systems (Ghent, Belgium), was found-
ed (Van Lijsebettens et al., 2013 and references 
therein) and the GM technology was soon em-
ployed worldwide both in fundamental science to 
study gene function and in agriculture to produce 
transgenic crops with useful agronomic traits. The 
commercialization of GM crops started in 1996. 
Since then, the acreage of GM crops cultivated 
worldly has increased steadily to up to 100-fold 
the area planted. The average agronomic and 
economic benefits of GM crops are large and sig-
nificant (Klümper and Qaim, 2014) as is evidenced 
both in developed and developing countries. The 
agricultural sector is probably the segment of 
biotech industry that provides more benefits to 
the middle and low-income economies. In this 
introductory chapter we give an overview of the 
innovations in plant biotechnology that have been 
approved for commercialization or are at the late 
stages of development and their application to 
agriculture, agroforestry, industrial processes, 
and pharmaceutical industry.
Global GM crop plants
Genetic engineering has the potential to address 
the critical constrains of sustainable agriculture 
and the need for sufficient quantity of healthy food, 
feed, and biomass feedstock for the industry as well, 
but GM crops have delivered only a limited range of 
agronomic traits for the agriculture production. Of 
the possible GM crop options that have ever been 
commercialized in the world, only nine GM crops 
are grown commercially worldwide, among which 
soybean (Glycine max), maize (Zea mays), cotton 
(Gossypium hirsutum), and canola (Brassica napus) 
account for 99% of the worldwide GM crop acreage. 
In 2014, the largest share (50%) was for GM soy-
beans, followed by maize (30%), cotton (14%), and 
canola (5%) (James, 2014). Other crops that account 
for 1% of global GM planting are alfalfa (Medicago 
sativa), sugar beet (Beta vulgaris), papaya (Carica 
papaya), squash (Cucurbita pepo), and eggplant (So-
lanum melongena). Only three traits, herbicide tol-
erance (HT), insect resistance (IR), and hybrid vigor 
have been generated and introduced in almost all 
GM crops grown commercially over the past 20 
years. In 2014, 57% of the world’s land surface of 
GM crops was HT, 15% IR, and 28% both HT and IR, 
called stacked traits, whereas other traits, such as 
virus resistance and drought tolerance, collectively 
account for less than 1%. The drought-tolerant bio-
tech corn varieties are cultivated since 2013 only in 
the USA (James, 2014).
 
In Africa, where the GM technology is most need-
ed to foster agricultural transformation, the out-
put is deceiving. Only three African countries 
cultivate GM crops: South Africa with 2.7 million 
ha of maize, soybean, and cotton; Sudan with 0.1 
million ha of cotton; and Burkina Faso with 0.5 
million ha of cotton (James, 2014).
 
Despite this quite unsatisfying output in terms of 
crops and traits, farmer’s acceptance as well as 
global income, production, and environmental 
impacts of these biotech crops are impressive. 
Farmers who have been granted the opportunity, 
quickly adopted GM crops. By 2014, millions of 
farmers in 28 countries worldwide have chosen 
to plant GM crops over 181.5 million ha and grow 
almost half of the global plantings of soybean, 
maize, cotton, and canola. The GM traits have 
provided logistical advantages, risk reductions, 
and economic benefits.
 
Brookes and Barfoot (2015a) analyzed the changes 
in farm income thanks to the impact of GM 
16
technologies on yields, key production costs, no-
tably seed cost and crop protection expenditure, 
but also impact on energy and labor costs where 
data were available, and the prospect of planting 
a second crop in one season. At the global lev-
el, GM technology has had a significant positive 
impact on farm income. The net economic bene-
fits of the four major GM crops (soybeans, maize, 
canola, and cotton) at the farm level amount to 
US$ 133.4 billion for 18 years of commercializa-
tion between 1996 and 2013. Approximately 70% 
of these gains have derived from yield and pro-
duction gains and 30% from cost savings, such 
as less ploughing, fewer pesticide sprays, and 
less labor. In 2013, the direct global farm income 
benefit was US$ 20.5 billion, which is equivalent 
to a 5.5% addition to the global production value 
of the four main crops. As expected, US farmers 
have been the largest beneficiaries of increased 
incomes, because they adopted the GM technol-
ogy early on and more than 80% of the four crops 
are GM since several years. More relevant is that 
farmers in developing and emerging economies 
got approximately 50% of the economic gains. 
The additional income benefits for soybean and 
maize farmers in South America (Argentina, Bo-
livia, Brazil, Colombia, Paraguay, and Uruguay) 
and cotton farmers in Asia (China and India) were 
US$ 31.1 billion and US$ 32.9 billion respective-
ly. Table 1 summarizes the economic impact of 
GM crops since their first commercialization year 
to 2013.
 
GM technology has also contributed to reduce 
the agriculture’s environmental footprint by facil-
itating environmentally friendly farming practices 
(Brookes and Barfoot 2015b). The GM IR traits 
replaced insecticides used to control pest. Since 
Biotech crop Total cumulative farmer’s 
income benefit 1996-2013 
(US$ billions)
Biotech trait Type of benefit Country
Soybean 14.8 HT soybeans (1st gener-
ation)
Lower production costs Brazil, USA, Canada, Uru-
guay, South Africa
Lower production costs + 
second crop gains
Argentina, Paraguay
Lower production costs + 
yield gains
Mexico, Bolivia, Romenia
HT soybean (2nd gener-
ation with higher yield 
potential)
Lower production costs + 
yield gains
USA, Canada
HT/IR soybean Cost savings as 1st 
generation HT soybean + 
insecticide savings + yield 
gains
Brazil, Argentina, Paraguay, 
Uruguay
Maize 7.36 HT maize Lower production costs USA, Canada, South Africa, 
Colombia
Lower production costs + 
yield gains
Argentina, Brazil, Philip-
pines
37.2 IR maize (resistance to corn 
boring pests)
Yields gains USA, South Africa, Hondu-
ras, Argentina, Philippines, 
Spain, Uruguay, Colombia, 
Canada, Brazil, Paraguay
IR maize (resistance to 
rootworm pests)
Yield gains USA, Canada
Cotton 1.49 HT cotton Lower production costs USA, South Africa, Aus-
tralia, Argentina, Uruguay, 
Paraguay
Lower production costs + 
yield gains
Brazil, Mexico, Colombia
40.78 IR cotton Yield gains USA, China, South Africa, 
Mexico, Argentina, India, 
Colombia, Burkina Faso, 
Pakistan, Burma
Canola 4.3 HT canola (tolerant to 
glyphosate)
Mostly yield gains where 
replacing triazine-tolerant 
canola
Australia
HT (tolerant to glufosinate)/
hybrid vigor canola
Mostly yield gains USA, Canada
Sugarbeet 0.14 HT sugarbeet Mostly yield gains USA, Canada
Table 1. Farm level economic benefits of GM crops
Adapted from Brookes and Barfoot (2015a).
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1996, the active insecticide ingredient use in cot-
ton and maize was reduced by 239 million and 
71.7 million kg, respectively, with the highest ben-
efits for cotton, because its culture requires an 
intensive treatment regime with insecticides. The 
adoption of GM IR cotton in China and India re-
sulted in a cumulative decrease in insecticides of 
over 192 million kg for the period 1996-2013. IR 
soybeans were first grown commercially in 2013, 
mostly in Brazil, and the savings in active insecti-
cide amounts in that year was above 0.4 million 
kg, corresponding to 1% of the total soybean in-
secticide use.
The environmental gains associated with the use 
of GM HT traits are related to the application of 
more environmentally friendly products and to 
simplified changes in farming systems. The adop-
tion of conservation tillage has led to additional 
soil carbon sequestration and a reduction in trac-
tor fuel use that amounted to 7,012 million liters 
between 1996 and 2013 (Carpenter, 2011). Less 
fuel, associated with fewer insecticide and herbi-
cide sprays and less or no ploughing, correspond-
ed to 28,005 million kg of CO2 eliminated from the 
atmosphere or, in terms of car equivalents, to 
12.4 million cars off the road for a year (Brookes 
and Barfoot 2015b).
 
The higher productivity of the currently commer-
cialized GM crops alleviates the pressure to con-
vert additional land for agriculture. To achieve the 
same tonnage of food, feed, and fiber obtained 
during the 1996-2013 period, 132 additional mil-
lion ha would have been needed with convention-
al crops only (James, 2014).
GM crops approved for 
commercialization in the world
In contrast to the limited number of GM crops 
on the market, an important number of crops, 
events, and traits have received approval for 
commercialization. As of 11th October 2015, a to-
tal of 40 countries granted regulatory approvals 
to 29 GM plants and 383 GM events, covering 36 
GM traits for use as food, feed and/or for culti-
vation (www.isaaa.org/gmapprovaldatabase). The 
fast-growing number of approved GM trait-con-
taining varieties and hybrids shows that GM tech-
nology does not narrow the genetic diversity of 
the crop plant. In addition to the commercial HT 
and IR GM traits used to construct the vast ma-
jority of GM crops on the market, GM traits have 
been also approved for abiotic stress tolerance, 
altered growth/yield, disease resistance, modified 
product quality, and pollination control systems. 
Table 2 summarizes the GM traits approved per 
GM plant. Remarkably, 13 different GM traits aim 
to change product quality in 13 different crops.
A number of noteworthy biotech crops/traits have 
been recently approved. In November 2014, the 
US Department of Agriculture (USDA) endorsed 
commercial planting of two crops employing an 
RNA interference (RNAi) approach: a transgen-
ic alfalfa with reduced lignin for improving fiber 
digestibility via RNAi of caffeoyl coenzyme 3-O- 
methyltransferase gene involved on the synthe-
sis of guaiacyl lignin subunit and a potato (Sola-
num tuberosum) with reduced levels of several 
enzymes, among which one that produces the 
potentially carcinogenic metabolite acrylamide. 
This Innate™ potato (J.R. Simplot, Boise, Idaho) 
also suffers less wastage from bruising (Waltz, 
2015). The Enlist™ Duo for maize and soybean 
(Dow AgroSciences, Indianapolis, IN, USA) that 
contains two stacked genes to confer tolerance 
to the herbicides glyphosate and 2,4-D-choline 
was approved in Canada in April 2014 and in the 
USA in September 2014 (James, 2014). Approval 
of the Arctic Apples, genetically engineered to re-
sist browning associated with cuts and bruises by 
reduction of the browning-causing enzyme levels 
was granted by the USDA in February 2015 and 
by the Food and Drug Administration (USA) in 
March 2015.
 
Developing countries also generated and ap-
proved novel biotech plants. In 2013, Indonesia 
ratified the environmental certificate for cultiva-
tion of drought-tolerant sugarcane (Saccharum 
spp.). In Brazil, a virus-resistant bean (Phaseolus 
vulgaris) was approved in 2011 and is due for 
commercialization in 2016 and a GM eucalyptus 
Commercial trait GM trait GM Plant
Abiotic Stress Tolerance Drought stress tolerance Maize
Sugarcane
Altered Growth/Yield Enhanced photosynthesis/yield Soybean
Volumetric wood increase Eucalyptus
Disease Resistance Black spot bruise tolerance Potato
Viral disease resistance Bean
Papaya
Plum
Squash
Sweet pepper
Tomato
Herbicide Tolerance Glufosinate herbicide tolerance Argentine canola
Cotton
Maize
Polish canola
Rice
Sugar beet
Glyphosate herbicide tolerance Cotton
Creeping bent grass
Maize
Polish canola
Potato
Soybean
Sugar beet
Wheat
Isoxaflutole herbicide tolerance Soybean
Mesotrione herbicide tolerance Soybean
Oxynil herbicide tolerance Argentine canola
Cotton
Tobacco
Sulfonylurea herbicide tolerance Carnation
Cotton
Flax
Maize
Soybean
Insect Resistance Coleopteran insect resistance Maize
Potato
Lepidopteran insect resistance Cotton
Eggplant
Maize
Poplar
Rice
Soybean
Tomato
Multiple insect resistance Cotton
Maize
Poplar
Modified Product Quality Altered lignin production Alfalfa
Non-browning phenotype Apple
Modified oil/fatty acid Argentine canola
Soybean
Phytase production Argentine canola
Maize
Modified flower color Carnation
Petunia
Rose
Modified amino acid Maize
Modified alpha amylase Maize
Delayed ripening/senescence Melon
Tomato
Delayed fruit softening Tomato
Modified starch/carbohydrate Potato
Reduced acrylamide potential Potato
Anti-allergy Rice
Nicotine reduction Tobacco
Pollination control system Fertility restoration Maize
Male sterility Argentine canola
Chicory
Maize
Table 2. Global status of GM technology: GM crops approved for commercialization in at least one country
Note. Source: ISAAA GM approval data base
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(Eucalyptus sp.) in 2015 (James, 2014; www.isaaa.
org/gmapprovaldatabase). FuturaGene, owned by 
the Brazil–based Suzano Pulp and Paper compa-
ny and the second largest producer of eucalyptus 
pulp globally, developed the transgenic eucalyp-
tus that contains a gene encoding an Arabidopsis 
thaliana protein that facilitates cell wall expansion 
and accelerates growth. According to FuturaGene, 
the GM tree produces 20% more wood than the 
conventional variety and is ready for harvest in 
five and a half years instead of seven.
 
There is a growing interest in GM forest trees due 
to the increasing global trend for timber produc-
tion from plantations and bioenergy applications. 
Since forests can be grown on marginal lands, 
competition with land resources suitable for ag-
ricultural production can be avoided. At the same 
time, the increased productivity from bioengi-
neered forests will provide an option to protect 
native forests.
 
A few GM forest trees have been produced com-
mercially. In China, poplar (Populus sp.) trees are 
cultivated for uses in furniture, boat making, pa-
per and chopsticks, because of their flexibility and 
close wood grain. (ISAAA, 2015). Since 2000, Chi-
na produces GM poplars to fight Asian longhorn 
beetle that devastated 7.04 million ha of poplar. 
Three clones of Populus nigra were developed 
with the Bacillus thuringiensis (Bt) gene cry1Aa and 
a hybrid white poplar (Populus alba) was trans-
formed by fusion of cry1Aa and the gene coding 
for a proteinase inhibitor from Sagittaria sagittifo-
lia. In the transgenic poplar plantations, the fast 
spread of the target insect pests was inhibited 
effectively and the number of insecticide applica-
tions was significantly reduced. The performance 
of the Bt black poplar plantations is significantly 
better than that of the clones deployed locally, re-
sulting in a substantial 90% reduction in leaf dam-
age. In 2014, GM poplar was cultivated in 543 ha 
in China (James, 2014).
 
ArborGen Inc. (Ridgeville, SC, USA), a tree seedling 
company, has developed a GM loblolly pine (Pinus 
taeda) cultivar with enhanced density. Lobloblly 
pines are used for lumber, plywood, and paper 
(ISAAA, 2015). As none of the inserted genes are 
derived from plant pests, the USDA deregulated 
the GM loblolly pine that can be cultivated without 
undergoing environmental studies (http://www.
capitalpress.com/Timber/20150128/usda-can-
not-restrict-gmo-pine).
Near-term innovations
Regulatory constraints, with delaying approvals 
and increasing costs, have discouraged biotech 
innovations, except in big corporations. The cost 
of discovery, development, and authorization of 
a new biotech crop or trait has been estimated 
to be approximately US$ 136 million (Prado et al., 
2014). Notwithstanding, good Research and De-
velopment  projects continue to be pursued both 
in developed and developing countries. A wide va-
riety of plants are being generated for resilience 
to biotic and abiotic stresses, increased water or 
nitrogen use efficiency (NUE), and nutritional im-
provements (Ricroch and Hénard-Damave, 2015). 
The major multinational agribusiness corpora-
tions often collaborate with public institutions, 
private entities, and philanthropic organizations 
in the least developed countries, particularly 
in Africa. Other relevant innovations for non-
food purposes, such as pharmaceutical, biofuel, 
starch, paper and textile industries are being 
pursued in developed countries.
Sustainable trait management
Management of several sustainable biotech traits 
is quickly becoming available. The main multina-
tional seed corporations continue to develop GM 
traits directed to broad-spectrum herbicides and 
resistance to chewing insects on a wide range of 
species. Most of these innovations are related to 
stacking different HT and/or IR genes. Gene stack-
ing simplifies and enhances pest management as 
demonstrated by IR and weed HR based on a sin-
gle gene technology (Que et al., 2010).
 
Nonetheless, research continue to focus on other 
kinds of sustainable agronomic traits and sever-
al traits and crops in the pipeline resulting from 
both private and public endeavors that target the 
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developing world are about to be commercial-
ized. Some case studies are listed below.
Water-Efficient Maize for Africa (WEMA)
Agriculture requires more water than any oth-
er human activity. Drought is a threat to farms 
around the world and in Africa drought is one of 
the major factors that prevent good yields. The 
Food and Agriculture Organization of the United 
Nations estimates that by 2025 approximately 
480 million Africans could be living in areas of wa-
ter scarcity. To face this challenge, plant scientists 
are developing drought-tolerant traits. The WEMA 
project is a public-private partnership that aims 
to improve food security and livelihoods for small 
farmers in Sub-Saharan Africa by finding ways to 
double the maize yields. In this project, GM and 
non-GM technology, including marker-assisted 
breeding, are combined to generate hybrid maize 
seeds with increased water use efficiency and re-
sistance to insect pests. To this end, the Bt gene 
will be stacked with the drought-tolerance bio-
tech trait (MON87460) that expresses the Bacillus 
subtilis cold-shock protein B (cspB), licensed from 
Monsanto. (http://wema.aatf-africa.org).
 
Centro de Investigación y de Estudios Avanzados del 
Instituto Politécnico Nacional (CINVESTAV-IPN)
In Mexico, the biotech maize CIEA-9 was devel-
oped with enhanced adaptation to severe drought 
and extreme temperatures. The antisense RNA 
expression was used for silencing trehalase in the 
popular maize inbred line B73 (derived from Iowa 
Stiff Stalk Synthetic). This biotech maize requires 
20% less water, endures high temperatures (up to 
50°C), and the seeds germinates at 8°C, demon-
strating their ability to withstand cold at early de-
velopment stages (Ortiz et al., 2014). In 2012, the 
Government of Mexico granted 4 ha for experi-
mental release of CIEA-9 in Sinaloa (Mexico). This 
permit was the first delivered to a Mexican public 
research center since the biosafety law was au-
thorized (Wolf and Otero, 2015).
Centro Internacional de Mejoramiento de Maíz y 
Trigo (CYMMYT; International Maize and Wheat Im-
provement Center)
Over the past five years, this Mexican center has 
analyzed experimental releases of genetically en-
gineered drought-resistant wheat (Triticum sp.). 
All the different events tested in experimental tri-
als on 0.1-ha plots at the Tlaltizapan Morelos site 
were drought resistant (Wolf and Otero, 2015).
ArborGen Inc.
This Brazilian company developed a GM eucalyp-
tus tree that can withstand extremely low tem-
perature. It contains a cold-inducible promoter 
driving a C repeat-binding protein from A. thalia-
na. This biotech tree combines the fast-growing 
and highly desirable fiber quality characteristics 
of a known Brazilian eucalyptus variety that can 
withstand freezing temperatures. Transgenic 
freeze-tolerant eucalyptus can grow up to 52.4 
feet (15.97 m) at 16.8oF (-8.4°C), compared to 
the control trees that grew only 0.3 feet (9 cm) 
(Hinchee et al., 2011). This freeze-tolerant tropical 
eucalyptus product (AGEH427) is currently going 
through the government review process for de-
regulation in the USA (www.arborgen.com).
Arcadia Biosciences Inc. (Davis, CA, USA)
The NUE trait contributes to improve yields in 
N-limited environments and reduces fertilizer 
costs and N fertilizer pollution (Hirel et al., 2011). 
Among the various genetic engineering strategies 
for NUE enhancement in crops, the overexpres-
sion of the gene coding for alanine aminotrans-
ferase that increases N uptake at early growth 
stages is a very promising candidate for commer-
cialization. The intellectual property associated 
with this invention has been licensed to Arcadia 
Biosciences Inc. The company possesses the 
rights to use this gene technology in major ce-
reals, such as wheat, sorghum (Sorghum bicolor), 
rice, maize, and barley (Hordeum vulgare), as well 
as in sugarcane. Field trials have been execut-
ed for rice in China, for rice and wheat in India. 
Its value for maize and rice is being assessed in 
Sub-Saharan Africa through private-public part-
nerships. Rice with NUE/water use efficiency and 
salt tolerance (NEWST) is on field trial in Uganda. 
The National Agricultural Research Organization 
(NARO), African Agriculture Technology Founda-
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tion (AATF), and Arcadia Biosciences cooperate 
on this research (Ortiz et al., 2014; James 2014).
Laboratorio Nacional de Genómica para la Biodiver-
sidad at CINVESTAV  
The National Laboratory of Genomics for Biodi-
versity at the Irapuato campus (Mexico) and a pri-
vate Mexican company are developing GM plants 
that will be able to absorb and optimize the use 
of phosphorus. The GM plants absorb phosphites 
rather than phosphates and so improve the use 
of fertilizers and weed control that compete for 
the phosphorus element. According to the devel-
opers, the trait can reduce the required amount 
of fertilizer by 30% to 50%, eliminates or reduces 
the use of herbicides, and is harmless to humans 
and animals. The group is developing a GM tobac-
co as first crop and, if successful, the trait will be 
introduced into maize for Africa in the near future 
(Wolf and Otero, 2015).
Examples of transgenic plants resistant to 
fungal disease
(1) Late blight of potato, one of the most devas-
tating diseases caused by a pathogen similar to 
fungi, Phytophthora infestans, accounts for 20% 
of potato harvest failures worldwide, translating 
into 14 million tons and valued at EURO 2.3 billion 
(Ortiz et al., 2014 and references therein). Sever-
al lines of transgenic potato containing R genes 
identified in wild relatives with high resistance to 
late blight have been produced (such as resistant 
genes from the wild Mexican relative Solanum bul-
bocastum, was used to breed the Fortuna cultivar 
and the Rpi-vnt1.1 gene isolated from Solanum 
venturii had been introduced into the potato vari-
ety Désiree). As these R genes had been identified 
in wild potato species, the use of the so-called cis-
genic technology facilitated the rapid transfer of 
these genes into cultivated potato varieties with-
out linkage drag. These plants have been shown 
to be resistant to late blight in several years of 
field tests (Gaffoor and Chopra, 2014 and refer-
ences therein; Ortiz et al., 2014, Jones, 2015).
(2)  In wheat, one of the most damaging fungal dis-
eases is powdery mildew. Transgenic wheat lines 
harboring different versions of a powdery mildew 
resistance gene (Pm3 R) have gone through field 
tests. Two years of field trials have revealed that 
the GM plants were more resistant to powdery 
mildew than the nontransgenic control plants 
(Gaffoor and Chopra, 2014).
(3)  The chestnut blight fungus secretes several 
toxic compounds, such as oxalic acid that low-
ers the pH of the surrounding plant tissue, with 
death of the infected tissue as a consequence. 
Plants transformed with a wheat gene encoding 
oxalate oxidase were able to detoxify the oxalic 
acid, thereby starving the fungus and restricting it 
to the bark of the tree (Castanea sp.). These plants 
were tolerant to the disease and have undergone 
rigorous laboratory testing and several years of 
successful field trials (Gaffoor and Chopra, 2014).
(4)  Banana (Musa sp.) plants have been engi-
neered to control a bacterial disease Xanthomonas 
wilt, better known as BXW. The transgenic plants 
containing genes from sweet pepper (Capsicum 
annuum) encoding a hypersensitive response-as-
sisting protein (Hrap) or a ferredoxin-like protein 
(Pflp) were evaluated over two successive crop 
cycles in a confined field trial in Uganda (Tripathi 
et al., 2014). Approximately 20% of the 40 Hrap 
lines and 16% of the 26 Pflp lines, for a total of 
11 transgenic lines, showed 100% resistance and 
retained the resistance in the ratoon crop. As elic-
itor-induced resistance is not specific against par-
ticular pathogens, this transgenic approach may 
also provide effective control of other bacterial 
diseases of banana, such as moko or blood dis-
ease in other parts of the world. Nearly 15 million 
people either rely on bananas for their income or 
consumption, making it an important food and 
cash crop in the Great Lakes region of East Afri-
ca. Food security studies revealed that in Uganda, 
Rwanda, and Burundi, bananas constitute >30% 
of the daily per capita caloric intake, rising to 60% 
in some regions (Tripathi et al., 2014).
Other ongoing biotech crop research activities for 
sustainable management that are on field trials 
in Africa include: (i) IR cowpea (Vigna unguicula-
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ta) in Burkina Faso (L’Institut pour l’Etude et la 
Recherche Agronomique, AATF, Network for the 
Genetic Development of Cowpea, and The Com-
monwealth Scientific and Industrial Research 
Organization), Ghana (AATF and Savanna Agricul-
tural Research Institute), and Nigeria (AATF and 
Institute of Agricultural Research); (ii) virus-resist-
ant cassava (Manihot esculenta) in Nigeria (Nation-
al Root Crops Research Institute), Kenya (Kenya 
Agricultural and Livestock Research organization 
[KALRO], International Institute of Tropical Ag-
riculture [IITA], Danforth Plant Science Center 
[DDPSC], and Masinde Murilo University of Sci-
ence and Technology), and Uganda (NARO, DDP-
SC, and IITA); (iii) Fungal resistance and drought/
salt-tolerant wheat in Egypt (Agricultural Genetic 
Engineering Research Institute); (iv) Virus resistant 
sweet potato Ipomoea batatas) in Kenya (KALCRO 
and DDPSC), (vi) IR sweet potato in Uganda (NARO 
and DDPSC); and (vii) nematode-resistant banana 
(NARO and University of Leeds, UK) (James, 2014).
Output traits for food and feed
Nutritionally enhanced food crops
 
A few nutritionally enhanced food crops have un-
dergone safety approval, namely maize with in-
creased lysine content and canola and a number 
of GM soybeans with improved fatty acid profile, 
including high stearidonic acid, an intermediate of 
omega-3-Fatty Acid. However, the last decade wit-
nessed great progress in R&D to generate nutri-
tionally improved biotech food crops specifically 
for targeting low-income families. Addressing nu-
tritional deficiencies by gene engineering would 
lead to decreased healthcare costs and increased 
economic performance. Biofortified staple crops 
harboring essential micronutrients to benefit the 
world’s poor and new functional GM food crops 
for enhancing human health are under develop-
ment. Several of these GM crops are currently be-
ing tested in developing countries. Some relevant 
examples are given below.
(1) Golden Rice, named for its golden color due 
to its high β-carotene content, is one of the first 
examples of a GM staple crop that was specifical-
ly designed to combat malnutrition and vitamin A 
(VitA) deficiency, because it is an essential nutri-
ent needed for the visual system, growth, devel-
opment, and a healthy immune system. Golden 
Rice was generated by the research group of Ingo 
Potrykus (ETH Zürich, Switzerland) (Ye et al., 2000) 
to offer a viable solution for eye damage of three 
million preschool-aged children due to VitA lack. 
The GM rice (GR1) was engineered with two genes 
from other organisms (daffodil [Narcissus poet-
icus] and the bacterium Erwinia uredovoia) that 
reconstitute the carotenoid biosynthetic pathway 
within the rice genome (Tang et al., 2009). The cur-
rent Golden Rice version, known as GR2, utilizes 
genes from two distinct proVitA pathways, includ-
ing the maize phytoene synthesis gene instead of 
the analogous daffodil gene used in the GR1 rice. 
Golden rice can produce β-carotene amounts 
that were up to 35 μg/g dry rice. Bioavailability 
testing has confirmed that Golden Rice is an ef-
fective source of VitA in humans (Hefferon, 2015 
and references therein).
(2)  Transgenic biofortified rice has also been engi-
neered to combat iron and folate deficiency, with 
improved mineral bioavailability, and with high 
content to essential amino acids, such as lysine 
(Blancquaert et al., 2015; Hefferon, 2015).
(3) The BioCassava Plus (BC+) program geneti-
cally engineered cassava with increased levels of 
iron and proVitA. Retention and bioavailability of 
transgenic cassava are similar to the findings on 
conventional biofortification research. The first 
field trials for a proVitA-biofortified cassava began 
in 2009, followed by trials for high-iron cassava, 
and delivery of the biofortified crops is expect-
ed in 2017. Additional traits included in BC+ are 
increased shelf life, reduced cyanide levels, and 
improved disease resistance (Tohme and Beyer, 
2014). The National Root Crops Research Insti-
tute of Nigeria is performing field trials with proVi-
tA-rich cassava (James, 2014).
(4)  Transgenic bananas with proVitA and iron are 
being developed by the NARO Uganda and the 
Queensland University of Technology. The per 
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capita consumption of bananas is estimated to 
be 0.7 kg per day in Uganda. Scientists applied 
the pro-Vitamin A genes used in Golden Rice to 
a popular local variety. Bananas with up to 20 
ppm proVitA have been generated and trials have 
started in Uganda. The ProVitA bananas are ex-
pected to be released in 2020. A human bioavail-
ability study began in late 2013 (Waltz, 2014). 
(5) Sorghum biofortified with VitA and bioavailable 
zinc and iron is tested by the Africa Harvest and 
Pioneer Hi-Bred in Nigeria (in collaboration with 
the National Biotechnology Development Agen-
cy) and in Kenya (in collaboration with KALRO) 
(James, 2014).
(6) Nutritional fatty acids associated with reducing 
coronary heart disease risks can be introduced 
into oilseed crops to improve human health. So 
far, 10 transgenes that have led to the accumu-
lation of high-value fatty acids in plants (Ortiz et 
al., 2014). High oleic acid GM soybeans produced 
by Pioneer Hi-Bred International, Inc. (Pioneer), 
a DuPont Company (Johnston, IA, USA), was the 
first biotech soybean product of this kind (Plen-
ish™). RNAi technology was used to decrease the 
expression of the endogenous soybean gene en-
coding fatty acid desaturase (gm-fad2-1) that pro-
duced seeds with an increased concentration of 
oleic acid (C18:1) and a correspondingly reduced 
concentration of linoleic acid (C18:2). The pur-
pose of this change in fatty acid profile is to pro-
vide a stable vegetable oil that is suitable for frying 
applications without the need for hydrogenation 
(De Maria, 2013).
(7) To synthesize Omega-3 long-chain polyun-
saturated fatty acids found routinely in fish oils, 
scientists of the Rothamsted Research Institute 
(Harpenden, UK) have metabolically engineered 
camelina (Camelina sativa) plants. The metabolic 
pathway to produce this fatty acid was reconsti-
tuted in camelina by substituting synthetic ver-
sions of up to seven genes from marine algae 
(Betancor et al., 2015). The levels of eiosapen-
taenoic acid and docosahexaenoic acid obtained 
were economically reasonable, thus representing 
a tangible success. Therefore, GM oilseeds can be 
a novel source of this essential oil. Omega-3 long-
chain polyunsaturated fatty acids are of great in-
terest due to their dietary benefits, such as im-
provements to brain function and development 
as well as for cardiovascular health. The camelina 
plants with a high content of these omega-3 oils 
in the laboratory/glasshouse are being evaluated 
for their performance in the field. Other beneficial 
fatty acids have also been made in plant seed oils, 
including γ-linolenic and stearidonic acid, as well 
as arachidonic acid (Hefferon, 2015).
(8) Transgenic tomato (Solanum lycopersicum) 
fruits with threefold enhanced hydrophilic an-
tioxidant capacity have been obtained through 
metabolic engineering. The “purple” tomato con-
tains genes from two snapdragon (Antirrhinum 
majus) transcription factors Delila and Rosea1 
that control anthocyanin biosynthesis (Butelli et 
al., 2008). Anthocyanins, compounds found in 
blueberries (Cyanococcus sp.) and cranberries 
(Vaccinium sp.) are believed to fight cardiovascu-
lar diseases and exhibit anti-inflammatory prop-
erties. Tomatoes were chosen because they are 
quite affordable antioxidant sources. The GM 
tomato with an as much as 30% significantly ex-
tended life span in the cancer-prone mice (Mus 
musculus), is currently being tested on heart pa-
tients in Britain (Hefferon, 2015). A recent study 
shows that the purple tomato not only is more 
healthy, but also has a longer shelf life and is 
more resistant to diseases than not GM toma-
toes (Zhang et al., 2013).
(9) Transgenic tomato plants that accumulat-
ed trans-resveratrol and trans-resveratrol-glu-
copyranoside have been obtained by transfor-
mation with the stilbene gene from grape (Vitis 
vinifera). These GM tomato lines showed a sig-
nificantly increased antioxidant capability and 
ascorbate content. The GM tomato extracts were 
able to counteract the pro-inflammatory effects 
of phorbol ester in a culture of monocyte-mac-
rophages (Hefferon, 2015).
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Nutrionally enhanced feed crops
GM feed crops have been developed to improve 
the nutritional value of animal feed as well as to 
produce more environmentally friendly manure. 
Biotech crops engineered with increased levels of 
amino acids are an alternative to the direct ad-
dition of supplemental amino acids in animal di-
ets. Examples of these types of crops include GM 
maize with enhanced production and accumula-
tion of free lysine in the corn kernel; protein-en-
riched GM soybean with more digestible lysine, 
methionine, threonine, and valine; high-methio-
nine GM lupine (Lupinus sp.); high-tryptophan 
GM rice; and GM alfalfa with increased levels of 
cysteine, methionine, aspartate, and lysine (ISAAA, 
2012; Hefferon, 2015).
 
GM feed crops with phytase enzyme have been 
shown to improve phosphorus availability. 
Non-ruminants cannot efficiently absorb phos-
phorus stored in plants as phytate salts. The un-
digested phosphates excreted by these animals 
can accumulate in the soil and water, leading to 
phosphorous pollution and organic matter ac-
cumulation. In addition, phytic acid forms insolu-
ble salts with zinc and other cations that reduce 
the bioavailability of trace minerals. GM corn, 
soybean, canola, and wheat expressing phytase 
transgenes have shown a positive effect on per-
formance, phosphorus retention, and excretion. 
Other antinutritive factors that have been tackled 
by plant gene engineering include GM soybeans 
with reduced levels of the antinutritive oligosa-
charides raffinose and stachyose and GM cotton 
seeds with low contents of the phenolic pigment 
gossypol (ISAAA, 2012).
Production of pharmaceuticals in 
biotech plants
Plants can be genetically engineered to harness 
endogenous metabolic pathways and the pro-
tein biosynthesis machinery to produce complex 
small-molecule compounds and recombinant bi-
ologicals. A number of plant species have been 
genetically engineered in several metabolic path-
ways to produce defined secondary metabolites 
of high pharmaceutical value, including paclitaxel, 
tropane, morphine, and terpenoid indole alka-
loids either as whole plants or cultured organs/
cells. Several advances are being implemented in 
terms of quality, purity, and yield, as well as proce-
dures to meet regulatory requirements to move 
from these products from proof-of-principle to 
commercial production (Fisher et al., 2015). 
 
One of the key features of plant-based produc-
tion platforms that distinguish them from other 
biological manufacturing concepts is the lack of 
a single biotechnological basis or a standardized 
platform. The technologies encompass stable 
transgene integration and transient expression 
in plants by means of bacterial, viral, or hybrid 
vectors (Chen and Lai, 2015). The platforms range 
from plant cells or simple plants, growing in bio-
reactors containing fully defined synthetic media, 
to whole plants growing in soil or in hydroponic 
environments. Whereas transient expression can 
produce very large amounts of the protein of in-
terest within a short time, transgenic plants are 
preferable when the transgenic seed production 
is needed. Many pharmaceutical products can be 
improved and made in a shortened time or on 
an enlarged scale in plant-based systems. These 
features are relevant when products can be pro-
duced with a superior quality and/or with plant 
specifications or when production scale and costs 
are important factors.
 
The production of recombinant pharmaceutical pro-
teins by means of using GM plants, often described 
as molecular farming, originated from the need for 
safe and inexpensive biopharmaceuticals in de-
veloping countries. Plants synthesizing expressing 
vaccine proteins can be grown using local farming 
techniques, only need to be partially processed, are 
easily transportable, and do not require refrigeration. 
Vaccines produced in food or feed crops effectively 
elicit an immune response to a particular pathogen 
when consumed fresh, dried, or lyophilized into a 
powder and reconstituted as a juice when needed. 
Therefore plant made vaccines could be easily avail-
able at low costs at remote regions of the planet 
(Hefferon, 2015).
These developments open interesting opportuni-
25
ties for low-income countries and investment in 
manufacturing pharmaceuticals in plants increas-
es globally. When production needs to be scaled 
up, the capital investments on plant-manufactur-
ing platforms in special molecular farming are ex-
pected to be considerably lower than with mam-
malian cell culture platforms. Companies in the 
USA and Europe have invested in the establish-
ment of new currently good plant-manufacturing 
practice facilities (Lössl and Clarke, 2013).
 
In 2012, an important breakthrough was achieved 
when the first plant-made pharmaceutical product 
was approved for use in humans, namely ELELY-
SO® (taliglucerase alfa) (Pfizer, New York, NY, USA), 
a recombinant form of human glucocerebrosidase 
produced in transgenic carrot (Daucus carota) root 
bioreactors for the treatment of the lysosomal 
storage disorder Gaucher’s disease (Stoger et al., 
2014). Another product gained global attention be-
cause of its role in an experimental Ebola therapy. 
The monoclonal antibody ZMapp, developed by 
Mapp Pharmaceuticals (Mountain View, CA, USA), 
was produced in tobacco plants at Kentucky Bio-
processing, a unit of Reynolds American. The drug 
was first successfully tested in humans during the 
2014 West Africa Ebola virus outbreak, but has not 
yet been subjected to a randomized controlled tri-
al (Zhang et al., 2014). This spectacular example of 
molecular farming proved it to be a fast and cheap 
way to produce novel biologicals.
 
Besides these success stories, a number of plant-de-
rived pharmaceutical products are currently on the 
market or undergoing clinical development for 
several clinical applications, including antibiotic-as-
sociated diarrhea, inflammatory bowel disease, 
osteoporosis, HCV HSV/HIV, vaccine, anti-caries 
antibody, and microbicide (Sack et al., 2015). More-
over, several pharmaceutical companies with plant-
based production facilities established commercial 
platforms for nonpharmaceutical products, such 
as cosmetics, veterinary pharmaceuticals, technical 
enzymes, research reagents, and media ingredient, 
as a manner to generate revenue during costly clin-
ical studies (Sack et al., 2015).
It is important to be aware that, as for all medi-
cal interventions, safety and legal issues are re-
quired for production and usage of plant-made 
pharmaceuticals. Depending on the plant pro-
duction system, different biosafety rules apply. 
Metabolites produced in cell suspension cultures 
based on medicinal plants are treated as natural 
products, whereas recombinant proteins pro-
duced in plants are considered products of GM 
organisms and, therefore, follow different regula-
tions. The development of plant cell suspension 
cultures as a platform for plant-made pharma-
ceuticals have been encouraged, partly because 
of the lack of a coherent regulatory framework 
for whole plant-derived pharmaceuticals (Fisher 
et al., 2015). Consequently, the first plant-derived 
recombinant pharmaceutical protein approved 
for human use was produced in plant cells. Not-
withstanding, there are impressive efforts to in-
corporate the latest regulatory innovations of 
industry-like platforms into whole plant-based 
manufacturing processes and to define updated 
guidelines (Fischer et al., 2015). With innovative 
and optimized production processes that can 
be scaled up and appropriate regulatory and 
biosafety frameworks, plant-derived recombinant 
proteins may offer high-volume and cost-effective 
delivery systems for many medical applications in 
this century (Mangan, 2014).
 
Examples of veterinary pharmaceuticals pro-
duced in feed include GM seeds for antibiotic re-
placement in animal farming, such as rice grains 
with human lactoferrin and/or lysozyme as an-
tibacterial and immunity-stimulating agents in 
chickens and pigs (Humphrey et al., 2002; Hu et 
al., 2010). Recently, Arabidopsis seeds have been 
transformed with an antibody against entero-
toxigenic Escherichia coli and used as a proof of 
concept for a passive oral immunization-based 
approach for piglets (Virdi et al., 2013).
Plant biotechnology for  
industrial applications
Innovations on output traits aiming at supporting 
sustainable processes in the chemical and fuel 
industry are lagging behind other plant biotech 
developments. To our knowledge, the only prod-
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uct approved for commercialization is the Amflo-
ra potato produced by BASF Plant Science (http://
www.sciencemag.org/news/2013/12/eu-court-an-
nuls-gm-potato-approval). This GM potato produc-
es starch composed almost exclusively of amylo-
pectin because the gene coding for starch synthase, 
involved in the synthesis of amylose had been 
switched off by RNAi strategy. As for certain indus-
trial uses of starch only the thickening properties of 
amylopectin are required, the gelling amylose com-
ponent is undesirable in many products and can in-
terfere with certain processes. The chemical mod-
ification or separation of these two components is 
associated with increased consumption of energy 
and water. The European Commission approved 
the Amflora potato for industrial use in 2010 and 
cultivation started on a small scale in the Czech Re-
public, Sweden, and Germany. However, in January 
2012, BASF Plant Science decided to stop marketing 
the Amflora potato in Europe due to lack of accept-
ance of GM crops in Europe and relocated its head-
quarters from Germany to the USA. In 2013, the 
European Union annulled the approval for BASF’s 
Amflora potato. 
 
Potato has also been engineered to pro-
duce high-amylose starch by suppression of 
the starch-branching enzyme SBE1 and SBE2 
through RNAi. Still at R&D stage, the production of 
high-amylose starches can be used in the produc-
tion of packaging material as well as film and coat-
ing from natural resources (Menzel et al., 2015).
Other biochemical pathways for the production 
of molecules for the chemical industry are ac-
tively engineered, but most are still at R&D stage, 
including the tailoring of oil composition for use 
as biofuel and bio-based lubricants in camelina 
and Jatropha curcas (Kim et al., 2014; Kim et al., 
2015); altered lignin content and composition to 
develop more efficient biofuels and biomaterial 
conversion processes in poplar, sorghum, and 
sugarcane (Fu et al., 2011; Bottcher et al., 2013; 
Van Aker et al., 2014). Sugarcane has also been 
transformed with microbial genes that produce 
cellulose-degrading enzymes to produce self-pro-
cessing plants (Harrison et al., 2011).
Plant biotechnology  
for phytoremediation
There are a rapidly increasing number of scientific 
publications relating to phytoremediation and an 
expanding number of ways in which plants can 
be used for effective remediation of contaminat-
ed soil, sludge, sediment, ground water, surface 
water, and wastewater. Several case studies have 
demonstrated that GM technologies have suc-
cessfully enabled phytoremediation to be tailored 
towards specific pollutants. Examples include 
model plants developed to degrade 2,4,6-trinitro-
toluene (TNT), hexahydro-1,3,5-trinitro-1,3,5-tri-
azine (RDX), trichloroethylene (TCE), and polychlo-
rinated biphenyls (PCBs) (Rylott et al., 2015). Focus 
is now turning from model plant systems to the 
transfer of this technology into plant species suit-
able for remediation in the field. One example is 
the transfer of rabbit cytochrome P450, 2E1 into 
poplar trees (Doty et al., 2007), based on the pio-
neering approach of expressing a single human 
2E1 in tobacco for increased degradation of TCE, 
vinyl chloride, carbon tetrachloride, chloroform 
and benzene (Doty et al., 2000; James et al., 2007).
Conclusion
Biotechnology provides to many of the challenges 
that our world faces today, from feeding and fuel-
ling a growing population, tackling a worldwide 
epidemic of neglected and chronic diseases, to 
mitigating the environmental impact of modern 
human societies. Plant biotechnology with focus 
on seed-varietal improvement, such as GM tech-
nology and molecular-assisted breeding, has gen-
erated products that help agriculture to achieve 
enhanced yields in a more sustainable manner. 
GM technology has brought significant improve-
ments to earned income, life quality, and per acre 
productivity. The global value of transgenic seed 
alone has been estimated at US$ 15.7 billion, rep-
resenting 35% of the approximately US$ 45 billion 
commercial seed market (James, 2014), which is a 
formidable achievement, considering the very lim-
ited number of commercialized crops and traits. 
Relevant is also that farmers in developing coun-
tries touched approximately 50% of the economic 
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gains of the GM technology and that GM crops 
generated a provisional benefit of US$ 68.21 bil-
lion between 1996-2013 (Brookes and Barfoot, 
2015a) for growers of which 94.1% or more than 
16.9 million were smallholder and resource-poor 
farmers from developing countries (James, 2014).
 
Although impressive, these figures are less re-
markable when challenged with the statistics of 
800 million people around the world, or 78% of 
the world’s poor people, who live in rural areas 
and rely on farming, livestock, aquaculture, and 
other agricultural work for their subsistence (www.
worldbank.org/en/news/feature/2014/11/12/
for-up-to-800-million-rural-poor-a-strong-world-
bank-commitment-to-agriculture) and for whom 
the GM technologies do not satisfactorily reach 
the needs in the least developed countries. Al-
though more than half of the global GM crop area 
is located in developing countries, the major GM 
crops commercialized today, i.e. soybean, maize, 
and canola, except cotton, are grown on large 
farms in Latin America and do not match the in-
terests of most smallholder farmers in the least 
developed countries. Crops of relevance to mar-
ginal environments, such as millet (Pennisetum 
glaucum), groundnut (Arachis sp.), cowpea, com-
mon bean (Phaseolus vulgaris), chickpea (Cicer ari-
etinum), pigeon pea (Cajanus cajan), cassava, yam 
(Dioscorea batatas), and sweet potato, to name a 
few, have been mostly ignored by GM technology.
 
Because of their restricted trade, these so-called 
neglected underutilized crop species (NUCS) 
present little economic interest for commercial 
seed companies, but they have the potential to 
play an important role in the improvement of 
food security by contributing to food quality and 
dietary diversity. NUCS may also increase sustain-
ability of agriculture, because they are believed to 
be well adapted to niche-specific environments, 
such as marginal and harsh lands, and to need 
a low input. As such, NUCS can help mitigate the 
impact of climate change on food production. 
However, these crops have been abandoned by 
researchers and farmers in favor of major crops 
that are sometimes promoted even in less suit-
able areas (Chivenge et al., 2015). Moreover, the 
limited information on the genetic potential, 
agronomy, water requirements, and nutrition of 
NUCS remains a hindrance to their development 
and competitiveness. Therefore, actions have to 
be taken to overcome the constraints and obsta-
cles for the cultivation of NUCS in regions where 
the uncertain climatic future can hamper food 
security, including acceleration of research to im-
prove genetics and management as well as cul-
tural acceptability and marketing.
 
Biotechnology tools can quicken the genetic im-
provement of NUCS. The GM approach can be 
used to introduce directly the desired sustaina-
ble management and the valuable output traits 
into varieties well adapted to local growing con-
ditions. A major technological constraint is plant 
transformation that is critical for the development 
of biotech crops, for which GM techniques, such 
as transgenics, cisgenics, or by precision breed-
ing, are required in the developmental process. 
The lack of efficient transformation protocols and 
breeding programs for geographical niche crops 
is in blatant contrast with the continuous striv-
ing for simpler, more robust, and more efficient 
transformation protocols for crop species for in-
tensive agriculture.
 
There have been significant advances in the de-
velopment of GM crops that can deliver food with 
health benefits beyond basic nutrition and in tar-
geting small-market crops and a few NUCS for 
quality traits. These so-called second-generation 
traits will soon reach the market. The innovations 
coincide with an increasing consumer demand 
for healthy and nutritious food. The public sector 
shares a great deal of the research done in this field 
and public-private partnerships excel in translating 
the proof-of-concept to a marketable product.
 
Plant-made pharmaceuticals have become a ma-
jor focus point since 2010, when realistic oppor-
tunities for commercial development emerged. 
Plant-manufacturing platforms for pharmaceu-
ticals or molecular farming open interesting 
prospects for low-income countries, where large 
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quantities of medicines need to be provided on a 
regular basis. Cost-effective local focus and nee-
dle-free deployment can be of great help for the 
treatment of tropical diseases.
 
In the industrial sector, plant biotechnology has 
the potential not only to generate more produc-
tive biomass feedstocks and minimize inputs, but 
also to develop more efficient biofuels, chemicals, 
and bio-material conversion processes. A num-
ber of nonfood crops improved with sustainable 
management have gone through the regulatory 
process. Additionally several biochemical path-
ways are currently being explored for the devel-
opment of quality traits for the chemical industry 
and for phytoremediation (Ricroch and Hénard-
Damave, 2015).
 
Of the greatest technological gaps in the commer-
cialization of second-generation biofuels along 
with chemicals are the conversion processes that 
are costly, environmentally threatening, and time 
consuming. Advanced nonfood feedstocks have 
to be developed that can grow on marginal lands 
and simultaneously can decrease the costs of 
lignocellulosic biomass pretreatments. Numer-
ous projects are under consideration that aim at 
engineering lignin content and monomer compo-
sition to optimize lignin degradation (Harfouche 
et al., 2014).
 
Examination of the fast uptake of biotech crops 
on millions of hectares globally and of the current 
R&D pipelines impacting numerous plant species 
indicates that plant biotechnology will be a major 
tool to overcome the challenges of sustainabili-
ty and development. Developing and emerging 
economies have taken the lead in terms of adop-
tion of biotech crops and also in approvals of new 
transgenic crop varieties (James, 2014). As more 
actors become involved in R&D and more tech-
nologies are adapted and applied to new regions 
and local crops, the more developing countries 
will play a leading role in agricultural biotechnolo-
gy. In the near term, most of the developing world 
will continue to rely on development assistance 
and innovations, as well as on technology part-
nerships and joint ventures with companies from 
developed countries that look for access to large 
developing markets. However, as research capac-
ities increase, public sector institutes and private 
firms in emerging and low-income economies are 
likely to develop new biotech crops on their own. 
In the not too distant future, agricultural biotech 
research in developed countries could be sur-
passed in the same manner that production has 
already been.
 
The opportunities offered by plant biotechnolo-
gy have never been greater, but neither have the 
challenges been, among which the most daunt-
ing is public perception and its influence on the 
regulation of biotech crops. All GM crops are sub-
mitted to a rigorous battery of tests and regula-
tory scrutiny prior to commercialization. Typically, 
the properties of the GM crops are compared to 
those of the corresponding non-GM variety with 
respect to various potential risk factors. Such 
comparative analyses include agronomic, molec-
ular, compositional, toxicological, and nutritional 
assessments. Regulatory systems must ensure 
that all steps are in place to guarantee biosafe-
ty, but they must also ensure that none of these 
steps is unnecessary. Currently, the biggest con-
straint to commercialization of transgenic prod-
ucts is the regulatory delay, including, among oth-
ers, test repetition, slow review time, and requests 
by regulators for additional information, often not 
necessary to demonstrate safety, and lack of clar-
ity with respect to the regulatory requirements. 
Another source of delay is political interference 
in the biosafety regulatory process that hampers 
technologies developed by public-sector insti-
tutions or small private firms that, compared to 
large multinational corporations, have less finan-
cial flexibility to absorb the costs until the regu-
latory authority finally renders its decision (Bayer 
et al., 2010). Thus, the extensive time needed to 
complete a regulatory file may significantly reduce 
the net benefits of GM products.
 
The costs of compliance with biosafety regulation 
also deter low-income and emerging economies 
from considering GM technologies as a solution 
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to agricultural problems. Biotech developers 
must take into account not only the countries 
where the cultivation of the new biotech crops 
could take place, but also where the consump-
tion of such crops might ultimately occur. So, an 
emerging country that wants to export GM food 
to the developed world is confronted with regula-
tory frameworks that do not give it much latitude. 
Moreover, low-income and emerging economies 
will not be able to keep pace with the ever-chang-
ing regulatory requirements of the developed 
world and will clearly restrict their decision to ap-
ply GM technology.
 
Public perception of GM crops and food is influ-
enced by numerous factors, including access to 
information or misinformation, commercial ac-
tions by corporations, moral and ethical beliefs, 
and perceptions of personal benefit from the 
technology. Anti-GMO activists diffuse misinfor-
mation to uphold the belief that harm will come 
to those who consume foods made up of GM 
ingredients, heightening anxiety with the mass 
public as well as with public authorities (Blancke 
et al., 2015). This concerted opposition to GM 
crops resulted in a number of complex legal and 
regulatory issues that have halted cultivation and 
stymied plant research in Europe with disastrous 
consequences to the development of new crops 
varieties and their introduction to markets world-
wide. The best example is Golden Rice that has 
still not been approved for release in spite of its 
urgent need and readiness for well over a decade. 
Should concerns of this nature persist, R&D ef-
forts will probably be restricted to large agribusi-
ness corporations that will continue to focus on 
major intensive agriculture crops.
 
Nevertheless, there is no time to waste. The 
world’s overpopulation and the pressures on the 
Earth system require all the ingenuity human be-
ings can deliver. To ensure that the biotechnol-
ogies live up to the expectations, they will have 
to focus on the priorities that could slow, limit, or 
halt research and development, including neg-
ative public opinion and the lack of regulatory 
harmonization. Needless to say that markets and 
technology alone cannot promote the sustainable 
development of human societies. A deep trans-
formation of societal values in a holistic manner 
will be required that can only be achieved with 
strong political will.
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